We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Diagnostic Tool for Lyme Disease Testing Boasts Over 90% Accuracy

By LabMedica International staff writers
Posted on 23 Sep 2024

Lyme disease is on the rise globally, with an estimated 14% of the population having been infected at some point. More...

Many of these individuals experience chronic symptoms due to delayed diagnosis. A recent study found that 38% of Lyme patients continue to suffer from symptoms six months after their initial diagnosis, highlighting the need for better testing methods. Until now, tests for Lyme disease have been less than 50% accurate, particularly in the early stages, leading to numerous cases of misdiagnosis or undiagnosed patients, resulting in prolonged suffering. Now, a new test with over 90% accuracy, capable of detecting the disease at all stages, including the crucial first 14 days post-infection, represents a potential breakthrough in Lyme disease diagnosis.

Developed through a collaboration between Tulane University (New Orleans, LA, USA) and Focus on Lyme (Phoenix, AZ, USA), the new diagnostic, LymeSeek, is enhanced by machine learning and has the potential to transform Lyme disease detection. The test's high accuracy is achieved through a combination of multiple biomarkers and a unique algorithm, providing over 90% accuracy in all phases of the disease. Unlike other tests that claim similar accuracy but rely solely on two-tier testing, LymeSeek's accuracy is based on samples from the early stages of the disease, including cases with erythema migrans (EM) rash, PCR, and/or punch biopsy results, which are often missed by current testing methods.

This patented test will enable timely and precise diagnosis of Lyme disease during its most treatable phase. The current diagnostic process for Lyme disease involves multiple steps, takes over a week, and requires subjective interpretation. LymeSeek aims to replace this lengthy procedure, facilitating earlier diagnoses and reducing the incidence of chronic illness caused by delayed or missed diagnoses. Ongoing efforts are focused on further development and manufacturing, with plans to pursue early FDA clearance, aiming to make LymeSeek available to the public by the third quarter of 2026.

Related Links:
Tulane University 
Focus on Lyme


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.